ImmuCell (ICCC) Competitors $5.38 -0.12 (-2.18%) As of 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ICCC vs. ARTV, PRQR, NLTX, PROC, ZNTL, HURA, IKT, CYBN, CGEN, and CRDFShould you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Artiva Biotherapeutics (ARTV), ProQR Therapeutics (PRQR), Neoleukin Therapeutics (NLTX), Procaps Group (PROC), Zentalis Pharmaceuticals (ZNTL), TuHURA Biosciences (HURA), Inhibikase Therapeutics (IKT), Cybin (CYBN), Compugen (CGEN), and Cardiff Oncology (CRDF). These companies are all part of the "pharmaceutical products" industry. ImmuCell vs. Artiva Biotherapeutics ProQR Therapeutics Neoleukin Therapeutics Procaps Group Zentalis Pharmaceuticals TuHURA Biosciences Inhibikase Therapeutics Cybin Compugen Cardiff Oncology ImmuCell (NASDAQ:ICCC) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability. Which has higher valuation and earnings, ICCC or ARTV? Artiva Biotherapeutics has lower revenue, but higher earnings than ImmuCell. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuCell$17.47M2.74-$5.78M-$0.50-10.76Artiva BiotherapeuticsN/AN/AN/AN/AN/A Do analysts rate ICCC or ARTV? Artiva Biotherapeutics has a consensus target price of $21.00, suggesting a potential upside of 197.03%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than ImmuCell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ICCC or ARTV? In the previous week, ImmuCell had 4 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for ImmuCell and 0 mentions for Artiva Biotherapeutics. ImmuCell's average media sentiment score of 0.17 beat Artiva Biotherapeutics' score of 0.00 indicating that ImmuCell is being referred to more favorably in the media. Company Overall Sentiment ImmuCell Neutral Artiva Biotherapeutics Neutral Does the MarketBeat Community favor ICCC or ARTV? ImmuCell received 112 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 73.33% of users gave ImmuCell an outperform vote. CompanyUnderperformOutperformImmuCellOutperform Votes12173.33% Underperform Votes4426.67% Artiva BiotherapeuticsOutperform Votes9100.00% Underperform VotesNo Votes Do insiders and institutionals believe in ICCC or ARTV? 13.5% of ImmuCell shares are held by institutional investors. 6.6% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ICCC or ARTV more profitable? Artiva Biotherapeutics has a net margin of 0.00% compared to ImmuCell's net margin of -15.99%. Artiva Biotherapeutics' return on equity of 0.00% beat ImmuCell's return on equity.Company Net Margins Return on Equity Return on Assets ImmuCell-15.99% -15.32% -8.81% Artiva Biotherapeutics N/A N/A N/A SummaryArtiva Biotherapeutics beats ImmuCell on 7 of the 13 factors compared between the two stocks. Get ImmuCell News Delivered to You Automatically Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ICCC vs. The Competition Export to ExcelMetricImmuCellDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.94M$2.17B$5.39B$9.13BDividend YieldN/A0.66%5.37%4.00%P/E Ratio-10.765.1788.8317.53Price / Sales2.7492.771,284.8380.47Price / CashN/A16.2336.6032.90Price / Book1.673.434.964.69Net Income-$5.78M$29.98M$117.89M$224.57M7 Day Performance3.86%1.21%2.74%3.33%1 Month Performance22.00%-0.85%3.63%5.33%1 Year Performance6.11%-16.08%27.26%22.97% ImmuCell Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ICCCImmuCell0.1937 of 5 stars$5.38-2.2%N/A+3.7%$47.94M$17.47M-10.7670ARTVArtiva BiotherapeuticsN/A$7.66-18.1%$21.00+174.2%N/A$186.05M$2.60M0.0081Gap DownPRQRProQR Therapeutics2.7894 of 5 stars$2.27-6.2%$8.83+289.1%+13.9%$185.41M$17.88M-7.09180NLTXNeoleukin TherapeuticsN/A$19.58-8.9%N/A-44.8%$184.01MN/A-6.3090Gap DownHigh Trading VolumePROCProcaps GroupN/A$1.63+1.9%N/A-60.6%$183.90M$414.10M3.135,500Positive NewsGap UpZNTLZentalis Pharmaceuticals2.9642 of 5 stars$2.56-6.9%$10.00+290.6%-82.6%$182.44M$40.56M-1.03160Positive NewsHURATuHURA BiosciencesN/A$4.31-11.1%$13.00+201.6%N/A$182.25MN/A0.00N/APositive NewsIKTInhibikase Therapeutics1.647 of 5 stars$2.66-9.8%$6.50+144.4%+58.2%$178.73M$260,000.00-1.006News CoverageCYBNCybin2.8012 of 5 stars$8.90+0.1%$138.00+1,450.6%N/A$177.93MN/A-1.3450News CoveragePositive NewsCGENCompugen2.2916 of 5 stars$1.99+21.3%$4.00+101.0%+16.0%$177.58M$59.85M99.5070Gap UpHigh Trading VolumeCRDFCardiff Oncology2.1585 of 5 stars$3.47-3.9%$10.33+197.8%+128.5%$177.44M$688,000.00-3.6920Positive News Related Companies and Tools Related Companies ARTV Alternatives PRQR Alternatives NLTX Alternatives PROC Alternatives ZNTL Alternatives HURA Alternatives IKT Alternatives CYBN Alternatives CGEN Alternatives CRDF Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ICCC) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuCell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
